{
    "Disease activity (follow up: 6 months; assessed with DAS 28-ESR (Lower values – > benefit) (MCID -1.17)": {
        "No of studies": "4",
        "Study design": "observational studies",
        "Risk of bias": [
            "serious",
            "a"
        ],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": [
            "serious",
            "b"
        ],
        "Other considerations": "none",
        "Nº of patients": {
            "Switching to a 3rd TNF Inhibitor": "43",
            "switching to rituximab": "58"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 0.35 lower (1.82 lower to 1.12 higher)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "CRITICAL"
    },
    "Low disease activity (follow up: 6 months; assessed with DAS28 ≤ 3.2)": {
        "No of studies": "4",
        "Study design": "observational studies",
        "Risk of bias": [
            "serious",
            "a"
        ],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": [
            "very serious",
            "c"
        ],
        "Other considerations": "none",
        "Nº of patients": {
            "Switching to a 3rd TNF Inhibitor": "6/35 (17.1%)",
            "switching to rituximab": "20/69 (29.0%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 0.59 (0.26 to 1.34)",
            "Absolute (95% CI)": "119 fewer per 1,000 (from 214 fewer to 99 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    },
    "Disability (follow up: 1 year; assessed with HAQ-DI (Lower values – > benefit) (MCID -0.22 )": {
        "No of studies": "4",
        "Study design": "observational studies",
        "Risk of bias": [
            "serious",
            "a"
        ],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": [
            "very serious",
            "c"
        ],
        "Other considerations": "none",
        "Nº of patients": {
            "Switching to a 3rd TNF Inhibitor": "35",
            "switching to rituximab": "54"
        },
        "Effect": {
            "Relative (95% CI)": "-",
            "Absolute (95% CI)": "MD 0 (0.53 lower to 0.53 higher)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    },
    "Withdrawal due to lack of efficacy (follow up: 1 year)": {
        "No of studies": "4",
        "Study design": "observational studies",
        "Risk of bias": [
            "serious",
            "a"
        ],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": [
            "serious",
            "d"
        ],
        "Other considerations": "none",
        "Nº of patients": {
            "Switching to a 3rd TNF Inhibitor": "15/64 (23.4%)",
            "switching to rituximab": "10/90 (11.1%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 2.11 (1.01 to 4.39)",
            "Absolute (95% CI)": "123 more per 1,000 (from 1 more to 377 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    },
    "Withdrawal due to adverse events (follow up: 1 year)": {
        "No of studies": "4",
        "Study design": "observational studies",
        "Risk of bias": [
            "serious",
            "a"
        ],
        "Inconsistency": "not serious",
        "Indirectness": "not serious",
        "Imprecision": [
            "serious",
            "d"
        ],
        "Other considerations": "none",
        "Nº of patients": {
            "Switching to a 3rd TNF Inhibitor": "14/64 (21.9%)",
            "switching to rituximab": "1/90 (1.1%)"
        },
        "Effect": {
            "Relative (95% CI)": "RR 19.69 (2.66 to 145.95)",
            "Absolute (95% CI)": "208 more per 1,000 (from 18 more to 1,000 more)"
        },
        "Certainty": "⨁◯◯◯ VERY LOW",
        "Importance": "IMPORTANT"
    }
}